CAR-T Archives

April 14, 2025

Making CAR-T Cells Inside the Body (In Vivo) to Treat CLL

CAR-T is an effective but underused option in cancer. Successful engineering of CAR-T cells in vivo in nonhuman primates has now been achieved.

October 11, 2024

Predicting Which CLL Patients May Respond to CAR-T Therapy

Lisocabtagene Maraleucel (liso-cel), a CAR-T therapy, is effective but only in a minority of chronic lymphocytic leukemia (CLL) patients.

September 10, 2024

Early Study of Experimental CAR-T Therapy for B Cell Cancers

An experimental CAR-T cell therapy made from healthy donor T cells is being tested in an ongoing phase 1 clinical trial to treat B Cell cancers.

March 20, 2024

Liso-cel, a CAR-T Therapy for Double Refractory CLL

Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.

February 22, 2024

CAR-T Therapy for Richter’s Transformation

Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.

October 18, 2023

Liso-cel, CAR-T Therapy for Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) – ICML 2023

This research shows that senescence (biological aging) can occur in CAR-T cells, reducing their ability to kill cancer cells.

March 24, 2023

ASH 2022: Dr. Neil Kay on Senescence in CAR-T Cells

This research shows that senescence (biological aging) can occur in CAR-T cells, reducing their ability to kill cancer cells.

March 1, 2023

Navigating the Financial Aspects of CAR T-Cell Therapy

In this WebMD article, Dr. Koffman provides practical advice on how patients can receive assistance paying for this expensive and potentially lifesaving therapy.

November 18, 2022

ASH 2021: Bispecific Vγ9Vδ2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML

Very complex, promising research is currently underway to use humanized bispecific single-domain antibodies (bsVHH). But, unfortunately, harnessing the immune system can get very complicated. This article introduces an experimental antibody with a novel approach to fighting CLL / SLL.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

CAR-T

Making CAR-T Cells Inside the Body (In Vivo) to Treat CLL

Predicting Which CLL Patients May Respond to CAR-T Therapy

Early Study of Experimental CAR-T Therapy for B Cell Cancers

Liso-cel, a CAR-T Therapy for Double Refractory CLL

CAR-T Therapy for Richter’s Transformation

Liso-cel, CAR-T Therapy for Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) – ICML 2023

ASH 2022: Dr. Neil Kay on Senescence in CAR-T Cells

Navigating the Financial Aspects of CAR T-Cell Therapy

ASH 2021: Bispecific Vγ9Vδ2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT